PHILADELPHIA - Claims by California diet clinic operators that they were defrauded under the state's unfair competition law (UCL) by American Home Products' marketing of the since-withdrawn diet drugs Pondimin and Redux were dismissed April 9 by the fen-phen multidistrict litigation judge (In re: Diet Drugs (phentermine/fenfluramine/dexfenfluramine) Products Liability Litigation, MDL NO. 1203, Geoffrey Drew, M.D., et al. v. American Home Products Inc., No. 00-21044, E.D. Pa.; 2012 U.S. Dist. LEXIS 49319).